Dual-Target CAR T-Cell Therapy (Gracell Biotechnology)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDual-Target CAR T-Cell Therapy (Gracell Biotechnology)

Drug Alias NameDual-Target Product Candidates (Gracell Biotechnology)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionImmunostimulantsT lymphocytes stimulants

TargetsUpdating

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesGracell Biotechnologies Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGracell Biotechnologies Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A